Tirzepatide
US$ 21.64
is trulicity a glp-1 receptor agonists Semaglutide vs. Other Two patients taking the GLP-1
Description
Diabetes 41 , 467473 (2023)
The graphical abstract was created using BioRender
Given the risk that obesity represents to public health and the difficulty of achieving and maintaining weight loss via lifestyle changes alone, there is a need for pharmacological approaches to aid weight loss in some individuals
Copayments are expected to be high
